Truist Financial
ACAD icon

Truist Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Truist Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$749K Buy
29,622
+3,169
+12% +$69.7K ﹤0.01% 1945
2026
Q1 		$589K Sell
26,453
-3,381
-11% -$80.8K ﹤0.01% 1984
2025
Q4 		$797K Buy
29,834
+4,057
+16% +$96.9K ﹤0.01% 1790
2025
Q3 		$550K Sell
25,777
-11,064
-30% -$262K ﹤0.01% 1975
2025
Q2 		$795K Sell
36,841
-2,474
-6% -$46K ﹤0.01% 1717
2025
Q1 		$653K Sell
39,315
-10,303
-21% -$187K ﹤0.01% 1726
2024
Q4 		$910K Sell
49,618
-4,965
-9% -$80.1K ﹤0.01% 1597
2024
Q3 		$839K Buy
54,583
+4,577
+9% +$76.4K ﹤0.01% 1617
2024
Q2 		$813K Buy
50,006
+6,887
+16% +$111K ﹤0.01% 1709
2024
Q1 		$797K Sell
43,119
-20,807
-33% -$515K ﹤0.01% 1726
2023
Q4 		$2M Sell
63,926
-32,824
-34% -$784K ﹤0.01% 1257
2023
Q3 		$2.02M Buy
96,750
+32,068
+50% +$871K ﹤0.01% 1238
2023
Q2 		$1.55M Buy
64,682
+20,357
+46% +$452K ﹤0.01% 1371
2023
Q1 		$834K Buy
44,325
+6,539
+17% +$125K ﹤0.01% 1663
2022
Q4 		$602K Sell
37,786
-4,082
-10% -$63.8K ﹤0.01% 1832
2022
Q3 		$685K Sell
41,868
-7,513
-15% -$122K ﹤0.01% 1659
2022
Q2 		$696K Sell
49,381
-12,016
-20% -$224K ﹤0.01% 1719
2022
Q1 		$1.49M Sell
61,397
-20,861
-25% -$505K ﹤0.01% 1429
2021
Q4 		$1.92M Sell
82,258
-21,742
-21% -$437K ﹤0.01% 1315
2021
Q3 		$1.73M Buy
104,000
+16,973
+20% +$327K ﹤0.01% 1345
2021
Q2 		$2.12M Buy
87,027
+11,390
+15% +$257K ﹤0.01% 1262
2021
Q1 		$1.95M Buy
75,637
+32,911
+77% +$1.45M ﹤0.01% 1253
2020
Q4 		$2.28M Buy
42,726
+13,358
+45% +$663K ﹤0.01% 1117
2020
Q3 		$1.21M Buy
29,368
+13,002
+79% +$561K ﹤0.01% 1294
2020
Q2 		$793K Buy
16,366
+2,054
+14% +$98.6K ﹤0.01% 1390
2020
Q1 		$605K Buy
14,312
+1,211
+9% +$49.9K ﹤0.01% 1481
2019
Q4 		$561K Buy
+13,101
New +$570K ﹤0.01% 1770
2017
Q4 		– Sell
-5,836
Closed -$220K – 791
2017
Q3 		$220K Buy
+5,836
New +$190K ﹤0.01% 738

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Truist Financial's ACAD Position: Q2 2026 in Review

Truist Financial increased its Acadia Pharmaceuticals (ACAD) stake by 12% in Q2 2026, buying an estimated $69.7K and bringing the position to 29,622 shares worth $749K. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Truist Financial first reported a position in ACAD in Q3 2017 and has held it in 28 quarters since. The position peaked at $2.28M in Q4 2020. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Truist Financial held 29,622 shares of Acadia Pharmaceuticals worth $749K as of Q2 2026.
  • Truist Financial bought 3,169 Acadia Pharmaceuticals shares in Q2 2026, an estimated $69.7K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1945 holding.
  • Truist Financial first reported a position in Acadia Pharmaceuticals in Q3 2017 and has held it in 28 quarters since.
  • Truist Financial's Acadia Pharmaceuticals position peaked at $2.28M in Q4 2020.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.